Brookline Capital Management reiterated their buy rating on shares of Chiasma (NASDAQ:CHMA) in a report published on Wednesday morning.

Separately, ValuEngine upgraded Chiasma from a hold rating to a buy rating in a research note on Thursday, November 1st.

Chiasma stock opened at $3.40 on Wednesday. Chiasma has a 1-year low of $1.20 and a 1-year high of $4.87.

Chiasma (NASDAQ:CHMA) last posted its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.31) earnings per share for the quarter.

A number of hedge funds have recently modified their holdings of the stock. Acadian Asset Management LLC raised its holdings in Chiasma by 99.1% during the fourth quarter. Acadian Asset Management LLC now owns 22,647 shares of the biotechnology company’s stock worth $70,000 after purchasing an additional 11,273 shares during the last quarter. Renaissance Technologies LLC raised its holdings in Chiasma by 20.9% during the third quarter. Renaissance Technologies LLC now owns 82,700 shares of the biotechnology company’s stock worth $298,000 after purchasing an additional 14,300 shares during the last quarter. Citadel Advisors LLC raised its holdings in Chiasma by 100.6% during the third quarter. Citadel Advisors LLC now owns 35,656 shares of the biotechnology company’s stock worth $128,000 after purchasing an additional 17,881 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in Chiasma by 51.4% during the third quarter. Dimensional Fund Advisors LP now owns 80,986 shares of the biotechnology company’s stock worth $292,000 after purchasing an additional 27,505 shares during the last quarter. Finally, Vanguard Group Inc. raised its holdings in Chiasma by 42.8% during the third quarter. Vanguard Group Inc. now owns 324,625 shares of the biotechnology company’s stock worth $1,169,000 after purchasing an additional 97,272 shares during the last quarter. 61.02% of the stock is owned by hedge funds and other institutional investors.

About Chiasma

Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.

Read More: Does the Step Transaction Doctrine Affect a Backdoor Roth IRA?

Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.